Denosumab (XGEVA) for the 'prevention of skeletal-related events in adults with bone metastases from solid tumours’

In the treatment of bone metastases from solid tumors, the therapeutic value of s.c. denosumab is comparable with that of i.v. zoledronic acid.

This report is a summary of recommendations by Zorginstituut Nederland. The original text is in Dutch.